1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19483
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFountzilas, G.en
dc.contributor.authorTolis, C.en
dc.contributor.authorKalogera-Fountzila, A.en
dc.contributor.authorMisailidou, D.en
dc.contributor.authorTsekeris, P.en
dc.contributor.authorKarina, M.en
dc.contributor.authorNikolaou, A.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorAthanassiou, E.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorBamias, A.en
dc.contributor.authorZamboglou, N.en
dc.contributor.authorEconomopoulos, T.en
dc.contributor.authorKaranastassi, S.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorDaniilidis, J.en
dc.date.accessioned2015-11-24T19:00:07Z-
dc.date.available2015-11-24T19:00:07Z-
dc.identifier.issn1357-0560-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19483-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectCarcinoma, Squamous Cell/*drug therapy/pathology/*radiotherapyen
dc.subjectCisplatin/administration & dosageen
dc.subjectCombined Modality Therapyen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectHead and Neck Neoplasms/*drug therapy/pathology/*radiotherapyen
dc.subjectHumansen
dc.subjectInfusions, Intravenousen
dc.subjectInjections, Intravenousen
dc.subjectLeucovorin/administration & dosageen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/administration & dosageen
dc.subjectTreatment Outcomeen
dc.titlePaclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil followed by concomitant chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck: a Hellenic Cooperative Oncology Group Phase II Studyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1385/MO:22:3:269-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16110138-
heal.identifier.secondaryhttp://www.springerlink.com/content/vu32670533l67354/fulltext.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractThe primary objective of this phase II study was to access the complete response (CR) rate to a new innovative induction regimen in patients with locally advanced head and neck cancer (LA-HNC). From October 2000 until October 2003 a total of 38 eligible patients (33 men and 5 women) entered the study. The large majority of them presented with a performance status of 0-1 and with clinical stage IV disease. Treatment consisted of three cycles of induction chemotherapy (IC) with paclitaxel 175 mg/m2 in a 3-h infusion on d 1, leucovorin (LV) 200 mg/m2 over 20 min immediately followed by FU 400 mg/m2 bolus and then 600 mg/m2 as a 24-h continuous infusion on d 1 and 2 and a cisplatin 75 mg/m2 over 1-h infusion on d 2 every 3 wk. This was then followed by radiation (70 Gy) and weekly cisplatin 40 mg/m2. After the completion of IC, 6/38 (16%) patients had CR. The CR rate was increased to 66% post-concomitant chemoradiotherapy (CCRT). Neutropenia (37.5%), pain (62%), nausea/vomiting (21%), and alopecia (79%) were the most frequent side effects during IC. The most pronounced toxicities during chemoradiotherapy were stomatitis (62.5%) and xerostomia (53%). Median time to progression was 11.0 mo and median survival 16.7 mo. One- and 2-yr survival rates were 73% and 38%, respectively. In conclusion, this novel induction regimen is active, is well tolerated, and can be successfully followed by CCRT with weekly cisplatin. CCRT should remain standard treatment for patients with LA-HNC. Novel induction combinations, such as that reported in the present study, should be evaluated in combination with CCRT only in the context of clinical trials.en
heal.journalNameMed Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Fountzilas-2005-Paclitaxel, cisplati.pdf91.33 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons